{"id":"trastuzumab-injectable-solution","safety":{"commonSideEffects":[{"rate":"5-27%","effect":"Cardiotoxicity / left ventricular dysfunction"},{"rate":"20-40%","effect":"Infusion reactions"},{"rate":"10-20%","effect":"Nausea"},{"rate":"10-15%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Trastuzumab targets human epidermal growth factor receptor 2 (HER2), a protein overexpressed in certain breast cancers. By binding to HER2, it prevents ligand-induced signaling and recruits immune cells to destroy HER2-positive tumor cells through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).","oneSentence":"Trastuzumab is a monoclonal antibody that binds to HER2 receptors on cancer cells, blocking growth signals and triggering immune-mediated cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:39:52.212Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HER2-positive metastatic breast cancer"},{"name":"HER2-positive early-stage breast cancer (adjuvant and neoadjuvant settings)"}]},"trialDetails":[{"nctId":"NCT07214766","phase":"PHASE1","title":"A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants","status":"RECRUITING","sponsor":"Genentech, Inc.","startDate":"2025-10-17","conditions":"Healthy Participants","enrollment":312},{"nctId":"NCT04739761","phase":"PHASE3","title":"A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-06-22","conditions":"Breast Cancer","enrollment":506},{"nctId":"NCT07386938","phase":"PHASE3","title":"A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"R-Pharm","startDate":"2024-08-09","conditions":"Locally Advanced Breast Cancer, Metastatic Breast Cancer","enrollment":246},{"nctId":"NCT07086768","phase":"PHASE1","title":"Dose-Escalation and Dose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patients With Advanced or Metastatic Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Lei Zheng","startDate":"2026-01-01","conditions":"Solid Tumor, Advanced Solid Tumor, Metastatic Solid Tumor","enrollment":57},{"nctId":"NCT07095023","phase":"NA","title":"Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-08-15","conditions":"Breast Cancers","enrollment":112},{"nctId":"NCT06172127","phase":"PHASE2","title":"PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"MedSIR","startDate":"2024-07-22","conditions":"HER2-positive Breast Cancer","enrollment":165},{"nctId":"NCT04042051","phase":"PHASE1","title":"Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer","status":"TERMINATED","sponsor":"Cancer Trials Ireland","startDate":"2019-11-12","conditions":"HER2-positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer","enrollment":2},{"nctId":"NCT03767335","phase":"PHASE1","title":"MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Menarini Group","startDate":"2018-11-13","conditions":"Advanced or Metastatic Breast Cancer","enrollment":62},{"nctId":"NCT03432741","phase":"PHASE1","title":"Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2018-03-27","conditions":"Breast Adenocarcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma","enrollment":17},{"nctId":"NCT02705859","phase":"PHASE1","title":"Phase Ib/II Trial of coPANlisib in Combination With Trastuzumab in HER2-positive Breast Cancer. (Panther Study)","status":"COMPLETED","sponsor":"Cancer Trials Ireland","startDate":"2016-04","conditions":"HER2 Positive Breast Cancer","enrollment":26},{"nctId":"NCT05824975","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)","status":"RECRUITING","sponsor":"GI Innovation, Inc.","startDate":"2023-05-30","conditions":"Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS)","enrollment":358},{"nctId":"NCT05965479","phase":"PHASE2","title":"Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer","status":"RECRUITING","sponsor":"University of Southampton","startDate":"2024-04-10","conditions":"Gastrooesophageal Cancer","enrollment":25},{"nctId":"NCT02297698","phase":"PHASE2","title":"Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients","status":"COMPLETED","sponsor":"Cancer Insight, LLC","startDate":"2014-10","conditions":"Breast Cancer","enrollment":100},{"nctId":"NCT01875367","phase":"PHASE3","title":"Phase III to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast Cancer","status":"COMPLETED","sponsor":"Spanish Breast Cancer Research Group","startDate":"2013-09-18","conditions":"Breast Cancer","enrollment":166},{"nctId":"NCT05301010","phase":"PHASE3","title":"Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients","status":"COMPLETED","sponsor":"Nanogen Pharmaceutical Biotechnology Joint Stock Company","startDate":"2018-02-02","conditions":"Breast Cancer Metastatic, Breast Cancer Recurrent, Breast Cancer Female","enrollment":128},{"nctId":"NCT05301530","phase":"PHASE1","title":"Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients.","status":"COMPLETED","sponsor":"Nanogen Pharmaceutical Biotechnology Joint Stock Company","startDate":"2019-05-27","conditions":"Breast Cancer Metastatic, Breast Cancer Female, Breast Cancer Recurrent","enrollment":50},{"nctId":"NCT01989676","phase":"PHASE3","title":"A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-02-24","conditions":"Metastatic Breast Cancer","enrollment":707},{"nctId":"NCT02187744","phase":"PHASE3","title":"A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-09-23","conditions":"Early Breast Cancer","enrollment":226},{"nctId":"NCT01928615","phase":"PHASE2","title":"A Study of Subcutaneously Administered Herceptin (Trastuzumab) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2013-09","conditions":"Breast Cancer","enrollment":2}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Herceptin"],"phase":"phase_3","status":"active","brandName":"Trastuzumab Injectable Solution","genericName":"Trastuzumab Injectable Solution","companyName":"Spanish Breast Cancer Research Group","companyId":"spanish-breast-cancer-research-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Trastuzumab is a monoclonal antibody that binds to HER2 receptors on cancer cells, blocking growth signals and triggering immune-mediated cell death. Used for HER2-positive metastatic breast cancer, HER2-positive early-stage breast cancer (adjuvant and neoadjuvant settings).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}